Bruker buys mAb and immunoassay supplier InVivo

By Dan Stanton contact

- Last updated on GMT

Image: iStock/extender01
Image: iStock/extender01

Related tags: Monoclonal antibodies

Bruker has bolstered its molecular biologics and mass spectrometric offering through the acquisition of contract manufacturing organisation (CMO) InVivo Biotech.

The deal – financial details of which were not divulged – gives scientific instrumentation firm Bruker Corporation mammalian cell culture and protein production capabilities, allowing the firm to supply monoclonal antibodies to CMO customers.

InVivo will continue to operate under its existing name and management team, but the deal allows Berlin, Germany-based Bruker to offer purified mAbs derived from a collection of more than 3,000 different hybridoma clones producing human, rat or mouse monoclonals to its CMO customers, as well as a proprietary media for serum-free cultivation.

The company will also increase its portfolio of immunoassay components and research kits through the addition of nearby InVivo.

“The acquisition of InVivo is part of our strategy to expand our microbiology assay menu for our mass spectrometric MALDI Biotyper platform,”​ Bruker spokesman Winfried Busch told Outsourcing-Pharma.com.

The platform offers drugmakers molecular identification and taxonomical classification of microorganisms and can be used in environmental and pharmaceutical analysis within the preclinical space.

The addition of InVivo will also “support our activities in translational pathology research with the MALDI Tissuetyper, a system solution for the label free detection of protein biomarkers in tissue sections,”​ Busch added.

InVivo Biotech’s founders, Wolfgang Weglöhner and Siegmund Karasch, added in a statement the deal brings: “Expanded opportunities for our business using the global commercial infrastructure of Bruker, particularly for microbiology and pathology.

“With our molecular biology core products and CMO services, we anticipate significant growth and expansion opportunities."

Related news

Show more

Related products

show more

INDENA ALWAYS AT THE FOREFRONT FOR CDMO SERVICES

INDENA ALWAYS AT THE FOREFRONT FOR CDMO SERVICES

Indena | 25-Oct-2022 | Technical / White Paper

Indena is well known in the space of naturally derived molecules, with a know-how developed over its one hundred year history. At the same time, the company...

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Flexible Filling Solution for CMOs

Flexible Filling Solution for CMOs

Single Use Support GmBH | 18-May-2022 | Insight Guide

Achieving flexibility requires modularity of technologies.

CMOs and CDMOs aspire to be flexible for multiple applications. Efficient automated...

Related suppliers

Follow us

Products

View more

Webinars